Dr. Chirag Trivedi Haematologist & Bone Marrow Transplant Physician

This presentation analyzed maternal and fetal outcomes for patients undergoing treatment for Chronic Myeloid Leukemia (CML) with Tyrosine Kinase Inhibitor (TKI) therapy. The study focused on the clinical management of patients during pregnancy, evaluating the safety, risks, and health outcomes for both the mother and the infant when TKI therapy is involved in the treatment plan.

The research provided critical data regarding the feasibility of managing CML during pregnancy and highlighted key considerations for clinicians when balancing oncological stability with gestational health. The findings serve to guide treatment strategies and patient counseling for those navigating the complexities of CML while planning or experiencing a pregnancy.

This study presented a comparative analysis between low-dose and standard-dose Nivolumab regimens in the treatment of patients with relapsed or refractory Hodgkin Lymphoma. The presentation focused on evaluating the efficacy and clinical outcomes of these two distinct dosing approaches, providing a comparative look at how different concentrations impact patient disease progression and response rates.

The work contributed essential clinical evidence to the field of haematology, specifically regarding immunotherapy optimization. By comparing these dosing strategies, the presentation offered valuable insights into refining treatment protocols for patients facing relapsed or refractory Hodgkin Lymphoma, aimed at maximizing therapeutic efficacy while tailoring care to individual patient needs.

This presentation detailed the clinical outcomes and patient results following allogenic haematopoietic stem cell transplantation (HSCT) for lymphoma, based on a comprehensive review of single-center data. It emphasized the efficacy of the transplantation procedure, analyzing survival metrics, disease control, and the recovery process for patients who underwent this complex medical intervention.

The findings showcased the institution's experience and expertise in performing HSCT for lymphoma patients, serving as a platform for sharing successful methodologies. By reviewing the specific clinical data from this single-center experience, the study provided evidence-based insights into the success rates and long-term outcomes associated with allogenic stem cell transplantation for lymphoma management.

This early clinical investigation focused on the administration and effectiveness of low-dose Nivolumab specifically for patients with relapsed and refractory Hodgkin Lymphoma. As a single-center experience, it detailed the response rates, patient tolerance, and clinical efficacy observed when utilizing a reduced-dose strategy in a specialized haematology setting.

The presentation highlighted the potential of implementing reduced-dose protocols to achieve therapeutic responses in patients who have not responded to initial lines of treatment. This foundational work provided important insights into the clinical utility of low-dose immunotherapy and the role of single-center experiences in shaping evidence-based practices for treating aggressive haematological conditions.